REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicOvercoming Resistance to Immune Checkpoint Inhibitors: Mechanisms and Strategies in Cancer TherapyView all 7 articles
Advances in the Application of PD-1/PD-L1 Immunotherapy for Prostate Cancer: A Review
Provisionally accepted
- Sichuan Cancer Hospital and Institute, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Prostate cancer (PCa), the most prevalent malignancy among male genitourinary cancers, is distinguished by its immunologically "cold" phenotype with persistently high incidence and mortality. Radical prostatectomy and radiotherapy represent the current standard of care for localized prostate cancer. However, recurrence or progression occurs frequently, and advanced or metastatic disease is common at initial presentation. Recent progress in cancer immunotherapy reveals that modulation of immune responses represents an effective strategy for enhancing antitumor activity. Programmed Cell Death Protein 1 and Programmed Cell Death Ligand 1 (PD-1/PD-L1) inhibitors, which restore T-cell function and remodel the tumor immune microenvironment, have achieved clinical success in melanoma, lymphoma and non-small-cell lung cancer. Although their efficacy as monotherapy in PCa remains limited and optimal patient selection criteria are lacking, emerging evidence suggests that combination immunotherapy regimens may offer clinically significant benefits. This review critically evaluates current clinical trial outcomes involving PD-1/PD-L1 inhibitors for prostate cancer and outlines priority directions for future investigation.
Keywords: prostate cancer, PD-1/PD-L1, immune microenvironment, Immunotherapy, combined therapy
Received: 12 Jul 2025; Accepted: 04 Nov 2025.
Copyright: © 2025 Hu, Li, Chen, Liao and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shukui Zhou, jackten@aliyun.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.